SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
SCIENTURE (NASDAQ: SCNX) announced the start of commercial sales and fulfillment of initial orders for Arbli™ (losartan potassium) Oral Suspension 10 mg/mL, the first FDA‑approved ready‑to‑use losartan oral suspension.
Key commercial facts: the U.S. losartan market is ~$256M annual sales with ~71M prescriptions (IQVIA, MAT June 2025). Scienture launched a multi‑channel promotional campaign, finalized PBM‑led GPO agreements, and executed multiple GPO contracts expanding access to >2,500 healthcare institutions, with estimated potential penetration of 20% of the U.S. institutional market.
SCIENTURE (NASDAQ: SCNX) ha annunciato l'inizio delle vendite commerciali e l'evasione dei primi ordini per Arbli™ (losartan potassium) sospensione orale 10 mg/mL, la prima sospensione orale di losartan pronta all'uso approvata dalla FDA.
Fatti commerciali chiave: il mercato statunitense del losartan è di circa 256 milioni di dollari di vendite annue con circa 71 milioni di prescrizioni (IQVIA, MAT giugno 2025). Scienture ha avviato una campagna promozionale multicanale, finalizzato accordi GPO guidati dai PBM e stipulato numerosi contratti GPO che espandono l'accesso a 2.500 strutture sanitarie, con una penetrazione potenziale stimata del 20% del mercato istituzionale statunitense.
SCIENTURE (NASDAQ: SCNX) anunció el inicio de ventas comerciales y la tramitación de los primeros pedidos para Arbli™ (losartán potasio) suspensión oral 10 mg/mL, la primera suspensión oral de losartán lista para usar, aprobada por la FDA.
Datos comerciales clave: el mercado estadounidense de losartán es de unas ventas anuales de ~256 millones de dólares, con ~71 millones de prescripciones (IQVIA, MAT junio 2025). Scienture lanzó una campaña promocional multicanal, finalizó acuerdos GPO dirigidos por PBM y ejecutó varios contratos GPO que amplían el acceso a 2.500 instituciones de atención médica, con una penetración potencial estimada del 20% del mercado institucional de EE. UU.
SCIENTURE(NASDAQ: SCNX)는 Arbli™(losartan potassium) 구강 현탁액 10 mg/mL의 상업적 판매 시작 및 초기 주문 이행을 발표했습니다. FDA가 승인한 최초의 로사르탄 구강 현탁액입니다.
주요 상업 정보: 미국 로사르탄 시장은 연간 약 2억 5,600만 달러 매출, 약 7,100만 건 처방(IQVIA, MAT 2025년 6월 기준)입니다. Scienture는 다채널 홍보 캠페인을 시작했고 PBM 주도 GPO 계약을 확정했으며 다수의 GPO 계약을 체결해 2,500개의 의료기관에 대한 접근을 확대했고, 미국 기관 시장의 약 20% 침투 가능성이 있습니다.
SCIENTURE (NASDAQ: SCNX) a annoncé le début des ventes commerciales et l'exécution des premières commandes pour Arbli™ (losartan potassium) Suspension orale à 10 mg/mL, la première suspension orale de losartan prête à l’emploi approuvée par la FDA.
Faits commerciaux clés : le marché américain du losartan représente environ 256 millions de dollars de ventes annuelles avec environ 71 millions de prescriptions (IQVIA, MAT juin 2025). Scienture a lancé une campagne promotionnelle multicanal, finalisé des accords GPO dirigés par PBM et conclu plusieurs contrats GPO élargissant l’accès à 2 500 établissements de santé, avec une pénétration potentielle estimée de 20 % du marché institutionnel américain.
SCIENTURE (NASDAQ: SCNX) kündigte den Start des kommerziellen Vertriebs und die Abwicklung erster Aufträge für Arbli™ (Losartan-Kalium) Orale Suspension 10 mg/mL an, die erste FDA‑genehmigte Losartan‑Oral Suspension, die einsatzbereit ist.
Wichtige kommerzielle Fakten: Der US‑Losartan‑Markt umfasst ca. 256 Mio. USD Jahresumsatz bei ca. 71 Mio. Verschreibungen (IQVIA, MAT Juni 2025). Scienture hat eine Multi‑Channel‑Verkaufsförderung gestartet, PBM‑geführte GPO‑Vereinbarungen abgeschlossen und mehrere GPO‑Verträge abgeschlossen, die den Zugang zu 2.500 Gesundheitseinrichtungen erweitern, mit einer geschätzten Durchdringung von 20% des US‑Institutionalmarktes.
أعلنت SCIENTURE (بورصة ناسداك: SCNX) عن بدء البيع التجاري وتنفيذ الطلبات الأولية لـ Arbli™ (بوتاسيوم لوسارتان) تعليق فموي 10 ملغ/مل، أول تعليق فموي للوسارتان معتمد من FDA وجاهز للاستخدام.
حقائق تجارية رئيسية: سوق لوسارتان الأمريكي يقدَّر بنحو 256 مليون دولار من المبيعات السنوية وبنحو 71 مليون وصفة (IQVIA، MAT يونيو 2025). أطلقت Scienture حملة ترويجية متعددة القنوات، وأتمت اتفاقيات GPO تقودها PBM، ووقَّعت عدة عقود GPO توسِّع الوصول إلى 2,500 مؤسسة صحية، مع إمكانية اختراق مقدَّرة تبلغ 20% من السوق المؤسسي الأمريكي.
SCIENTURE（纳斯达克股票代码：SCNX）宣布开始商业销售并履行 Arbli™（钾洛沙坦）口服悬液 10 mg/mL 的首批订单，这是FDA批准的首个现成可用的洛沙坦口服悬液。
关键商业事实：美国洛沙坦市场年销售额约为2.56亿美元，约有7100万处方（IQVIA，2025年6月 MAT）。Scienture 启动了多渠道促销活动，完成以 PBM 为主导的 GPO 协议，并执行多项 GPO 合同，将进入范围扩展至 2,500 家医疗机构，预计在美国机构市场的渗透率约为 20%。
- First FDA‑approved ready‑to‑use losartan oral suspension
- Commercial launch with first customer orders fulfilled
- U.S. losartan market size: $256M annual sales; 71M prescriptions
- GPO agreements expand access to >2,500 healthcare institutions (≈20% institutional penetration)
- Estimated institutional penetration of 20% implies limited near‑term reach beyond contracted sites
Insights
Scienture has begun commercial sales of Arbli™, with institutional coverage deals and measurable market opportunity.
Arbli™ is described as the first FDA-approved ready-to-use oral suspension of losartan potassium, and the company reports initial order fulfillment and launch of a multi-channel promotional campaign. The release cites a U.S. losartan market size of
The company highlights finalized PBM-led GPO agreements and multiple GPO contracts that extend access to over
Dependencies and near-term risks include actual uptake by prescribers and institutions, the execution of promotional activities, and the conversion of formulary access into recurring orders. The announcement documents outreach to healthcare professionals and coverage agreements, which are necessary but not sufficient to ensure sustained demand. Monitor the cadence of shipment volumes, formulary placement depth across PBMs/GPOs, and real-world ordering trends over the next several quarters to assess adoption.
Company launches multi-channel promotional campaign to drive market adoption
U.S. losartan market totals
COMMACK, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced the start of commercial sales and fulfillment of the first customer orders for Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL, marking an important milestone in the Company’s growth as it begins to bring this differentiated product to market.
Arbli™ is the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium, designed to provide a safe, consistent, and convenient therapeutic option for patients requiring an alternative to solid dosage forms. According to IQVIA data (MAT June 2025), the U.S. losartan market totals approximately
As part of its commercial campaign, Scienture is executing targeted outreach for Arbli™ to healthcare professionals (HCPs) and has finalized PBM-Led GPO agreements for expanded commercial coverage and formulary access. In addition, Scienture has also formalized multiple commercial group purchasing organization (GPO) agreements, expanding Arbli’s market access to over 2,500 healthcare institutions nationwide. This includes hospitals, clinics, nursing homes, specialty pharmacies, long-term care facilities, and ambulatory centers, collectively representing potential penetration into an estimated
“The start of commercial sales for Arbli™ represents a major achievement for Scienture as we transition from development to execution,” commented Narasimhan Mani, President and co-CEO of Scienture. “As promotional efforts expand and demand builds across retail, institutional and long-term care markets, we see significant potential for sustained adoption and value creation.”
“Arbli™ embodies our mission to deliver patient-focused pharmaceutical solutions that improve access and convenience,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “We are encouraged by the early response from healthcare institutions and remain committed to expanding education, awareness, and availability of this first-of-its-kind treatment option.”
About Arbli™
Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
INDICATION
Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
- Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
IMPORTANT SAFETY INFORMATION
- Do not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
- Do not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli™ in patients with renal impairment (GFR <60 mL/min).
- Do not administer Arbli™ in patients with severe hepatic impairment. Arbli™ has not been studied in patients with severe hepatic impairment.
- The most common adverse reactions are (incidence ≥
2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.
Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About Hypertension
Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com
FAQ
What did SCIENTURE (SCNX) announce on October 23, 2025 about Arbli?
How large is the U.S. losartan market relevant to SCNX's Arbli (2025)?
What market access agreements did SCNX secure for Arbli?
What is Arbli's product differentiation for patients?
Which care settings will Arbli be available in through SCNX's agreements?
What commercial activities will support Arbli adoption for SCNX shareholders?
